We are live on ! Find out more
PS

Peter Svennilson Portfolio holdings

AUM $1.23B
1-Year Est. Return 301.34%
This Fund
S&P 500
This Quarter Est. Return
+9.61%
1 Year Est. Return
+301.34%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
+$29.8M
Cap. Flow
+$97.3M
Cap. Flow %
7.94%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$170M
2
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$5.67M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$43.7M
2
RAPT
RAPT Therapeutics
RAPT
+$31.8M
3
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$3.09M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$287M 23.39%
18,017,932
+310,954
+2% +$5.67M
RVMD icon
2
Revolution Medicines
RVMD
$39.9B
$278M 22.65%
7,977,384
– –
NRIX icon
3
Nurix Therapeutics
NRIX
$2.41B
$236M 19.24%
+6,755,881
New +$170M
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$181M 14.79%
703,812
-143,332
-17% -$31.8M
CNST
5
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$123M 10%
6,051,376
– –
ORIC icon
6
Oric Pharmaceuticals
ORIC
$1.15B
$119M 9.73%
4,768,181
– –
GRTS
7
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.3M 0.19%
869,493
-831,452
-49% -$3.09M
RCUS icon
8
Arcus Biosciences
RCUS
$3.55B
– –
-1,767,676
Closed -$43.7M

Similar funds

CT
CGM Trust Boston, Massachusetts $957M AUM
CAW
Cornerstone Advisors (Washington) Bellevue, Washington $936M AUM 8.77% 1-Year Est. Return
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
SFSG
Stearns Financial Services Group Greensboro, North Carolina $639M AUM 11.66% 1-Year Est. Return
KFA
Kays Financial Advisory Atlanta, Georgia $624M AUM 9.93% 1-Year Est. Return
11A
10-15 Associates Goshen, New York $516M AUM 7.62% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
IA
Independence Advisors Wayne, Pennsylvania $466M AUM 11.32% 1-Year Est. Return

Peter Svennilson's Q3 2020 Portfolio in Review

As of Q3 2020, Peter Svennilson held 8 positions worth $1.23B, up 2.5% from $1.2B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Peter Svennilson deployed $97.3M of net new capital in Q3 2020, opening 1 new position and adding to 1 existing holding. Its largest new stake was Nurix Therapeutics: 6,755,881 shares worth $236M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was RAPT Therapeutics, an estimated $31.8M trimmed.

  • Peter Svennilson's largest Q3 2020 buy was Nurix Therapeutics: 6,755,881 shares worth $236M.
  • Peter Svennilson added most to NGM Biopharmaceuticals, Inc. Common Stock in Q3 2020, an estimated $5.67M increase.
  • Peter Svennilson's biggest Q3 2020 reduction was RAPT Therapeutics, cutting an estimated $31.8M.
  • Peter Svennilson fully exited Arcus Biosciences in Q3 2020, selling an estimated $43.7M.
  • Peter Svennilson's ten largest holdings make up 100% of its $1.23B portfolio in Q3 2020.
  • Peter Svennilson opened 1 new position and closed 1 in Q3 2020.
  • Peter Svennilson's portfolio value rose 2.5% quarter-over-quarter to $1.23B.

Based on Peter Svennilson's 13F filing for Q3 2020, filed 4 Nov 2020.